BIOMAT Database Logo BIOMAT Database Logo

Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. 2023

Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
1Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.

To assess the real-world cardiovascular (CV) safety for sulfonylureas (SU), in comparison with dipeptidyl peptidase 4 inhibitors (DPP4i) and thiazolidinediones (TZD), through development of robust methodology for causal inference in a whole nation study. A cohort study was performed including people with type 2 diabetes diagnosed in Scotland before 31 December 2017, who failed to reach HbA1c 48 mmol/mol despite metformin monotherapy and initiated second-line pharmacotherapy (SU/DPP4i/TZD) on or after 1 January 2010. The primary outcome was composite major adverse cardiovascular events (MACE), including hospitalization for myocardial infarction, ischemic stroke, heart failure, and CV death. Secondary outcomes were each individual end point and all-cause death. Multivariable Cox proportional hazards regression and an instrumental variable (IV) approach were used to control confounding in a similar way to the randomization process in a randomized control trial. Comparing SU to non-SU (DPP4i/TZD), the hazard ratio (HR) for MACE was 1.00 (95% CI: 0.91-1.09) from the multivariable Cox regression and 1.02 (0.91-1.13) and 1.03 (0.91-1.16) using two different IVs. For all-cause death, the HR from Cox regression and the two IV analyses was 1.03 (0.94-1.13), 1.04 (0.93-1.17), and 1.03 (0.90-1.17). Our findings contribute to the understanding that second-line SU for glucose lowering are unlikely to increase CV risk or all-cause mortality. Given their potent efficacy, microvascular benefits, cost effectiveness, and widespread use, this study supports that SU should remain a part of the global diabetes treatment portfolio.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013453 Sulfonylurea Compounds A class of compounds in which a sulfone functional group is attached to UREA. Compounds, Sulfonylurea
D015331 Cohort Studies Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. Birth Cohort Studies,Birth Cohort Study,Closed Cohort Studies,Cohort Analysis,Concurrent Studies,Historical Cohort Studies,Incidence Studies,Analysis, Cohort,Cohort Studies, Closed,Cohort Studies, Historical,Studies, Closed Cohort,Studies, Concurrent,Studies, Historical Cohort,Analyses, Cohort,Closed Cohort Study,Cohort Analyses,Cohort Studies, Birth,Cohort Study,Cohort Study, Birth,Cohort Study, Closed,Cohort Study, Historical,Concurrent Study,Historical Cohort Study,Incidence Study,Studies, Birth Cohort,Studies, Cohort,Studies, Incidence,Study, Birth Cohort,Study, Closed Cohort,Study, Cohort,Study, Concurrent,Study, Historical Cohort,Study, Incidence
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D054873 Dipeptidyl-Peptidase IV Inhibitors Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. DPP-4 Inhibitor,DPP-4 Inhibitors,DPP-IV Inhibitor,DPP-IV Inhibitors,DPP4 Inhibitor,DPP4 Inhibitors,Dipeptidyl Peptidase 4 Inhibitor,Dipeptidyl-Peptidase 4 Inhibitor,Dipeptidyl-Peptidase IV Inhibitor,Gliptin,Gliptins,Dipeptidyl-Peptidase 4 Inhibitors,DPP 4 Inhibitor,DPP 4 Inhibitors,DPP IV Inhibitor,DPP IV Inhibitors,Dipeptidyl Peptidase 4 Inhibitors,Dipeptidyl Peptidase IV Inhibitor,Dipeptidyl Peptidase IV Inhibitors,Inhibitor, DPP-4,Inhibitor, DPP-IV,Inhibitor, DPP4,Inhibitor, Dipeptidyl-Peptidase 4,Inhibitor, Dipeptidyl-Peptidase IV

Related Publications

Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
July 2018, BMJ (Clinical research ed.),
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Sulfonylureas as second line treatment for type 2 diabetes.
July 2018, BMJ (Clinical research ed.),
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
February 2020, Diabetes, obesity & metabolism,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study.
July 2023, Cardiovascular diabetology,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.
May 2024, BMJ open diabetes research & care,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Sulfonylureas as second line therapy for type 2 diabetes among veterans: Results from a National Longitudinal Cohort Study.
August 2023, Primary care diabetes,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
October 2019, British journal of clinical pharmacology,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study.
June 2021, Diabetes, obesity & metabolism,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
June 2020, Cardiovascular diabetology,
Huan Wang, and Ruth L M Cordiner, and Yu Huang, and Louise Donnelly, and Simona Hapca, and Andrew Collier, and John McKnight, and Brian Kennon, and Fraser Gibb, and Paul McKeigue, and Sarah H Wild, and Helen Colhoun, and John Chalmers, and John Petrie, and Naveed Sattar, and Thomas MacDonald, and Rory J McCrimmon, and Daniel R Morales, and Ewan R Pearson, and
Hepatic and cardiovascular safety of acarbose among type 2 diabetes patients with end-stage renal disease: A nationwide population-based longitudinal study.
February 2021, Diabetes research and clinical practice,
Copied contents to your clipboard!